shr3824anovelselectiveinhibitorofrenalsodiumglucosecotransporter2exhibitsantidiabeticefficacyinrodentmodels

doi:10.1038/aps.2013.196

	shr3824anovelselectiveinhibitorofrenalsodiumglucosecotransporter2exhibitsantidiabeticefficacyinrodentmodels
	Yan Pangke 1; Zhang Lina 1; Feng Ying 1; Qu Hui 1; Qin Li 1; Zhang Lianshan 2; Leng Ying 1
刊名	actapharmacologicasinica
	2014
卷号	35 期号:5 页码:613
关键词	BETA-CELL DIFFERENTIATION IMPROVES GLYCEMIC CONTROL TYPE-2 DIABETES-MELLITUS CHRONIC HYPERGLYCEMIA INSULIN-SECRETION SGLT-2 INHIBITOR SKELETAL-MUSCLE RATS DAPAGLIFLOZIN EMPAGLIFLOZIN sodium glucose cotransporter 2 (SGLT2) SHR3824 dapagliflozin type 2 diabetes mellitus blood glucose insulin sensitivity beta-cell function
ISSN号	1671-4083
DOI	10.1038/aps.2013.196
英文摘要	Aim: The sodium glucose cotransporter 2 (SGLT2) plays an important role in renal glucose reabsorption, thus serves as a new target for the treatment of diabetes. The purpose of this study was to evaluate SHR3824 as a novel selective SGLT2 inhibitor and to characterize its in vivo effects on glucose homeostasis. The effects of chronic administration of SHR3824 on peripheral insulin sensitivity and pancreatic beta-cell function were also investigated.
语种	英语
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/283697]
专题	中国科学院上海药物研究所
作者单位	1.中国科学院上海药物研究所 2.Shanghai Hengrui Pharmaceuticals Co, Ltd
推荐引用方式 GB/T 7714	Yan Pangke,Zhang Lina,Feng Ying,et al. shr3824anovelselectiveinhibitorofrenalsodiumglucosecotransporter2exhibitsantidiabeticefficacyinrodentmodels[J]. actapharmacologicasinica,2014,35(5):613.
APA	Yan Pangke.,Zhang Lina.,Feng Ying.,Qu Hui.,Qin Li.,...&Leng Ying.(2014).shr3824anovelselectiveinhibitorofrenalsodiumglucosecotransporter2exhibitsantidiabeticefficacyinrodentmodels.actapharmacologicasinica,35(5),613.
MLA	Yan Pangke,et al."shr3824anovelselectiveinhibitorofrenalsodiumglucosecotransporter2exhibitsantidiabeticefficacyinrodentmodels".actapharmacologicasinica 35.5(2014):613.